Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Genuine questions
How much will he be paid?
Will he get share options?
Does it matter that he has not been a COO before? Could he lack the skills of a more seasoned COO?
In the RNS is says " Dr Sargent will join as a key member of the Company's senior leadership team (but not as a board director) and will report directly to Dr Jim Millen." Why would PYC or new COO not want to be a board director?
It took 5 attempts over 2 days to breech and hold above 2p, was fascinating watching the trade go thru today. Got to 2p and sells came in, got to 1.8p and the buyers returned, some chunky trades to 700k and several 400 / 300k's
Great day all, just read most of the 225 posts today, a month ago, we were averaging about 5!
Gordon, you asked about TR1's
We know there is a Gary Marshall. That info only came to light after Jim does a 6 month refresh of the share register. "if" he is building, then i guarantee we will not find out for another 6 months, anyone who goes TR1 here probably wishes to fly under the radar. I would love a TR1 to appear, from Gary or anyone else, but in the last 5 years, there has only been 1 who appeared, and that was Zahid Ali.
Saying that, there were 2 others before the raise, and they are not shown now, i assume that they are still holding, but their % is less than 3% due to dilution.
Ria...do keep up!
Syneos: via linkedin. Syneos Health R&D Advisory is the former Kinapse Advisory practice. We offer management consulting (Strategy and Operations) for organisation, process and technology transformation across R&D including R&D operations, clinical, regulatory, quality & compliance, PV/safety and medical affairs.
Could help with regulatory compliance with doing tool.
Also has links with Kings college London, this is also where 1 of the significant shareholders (before dilution) (Dr Zahid Ali) works as well as UCB.
The new COO
https://data-lead.com/person/name/Peter+Sargent/id/32315412/v/8637d
https://uk.linkedin.com/in/peter-sargent-718085a?challengeId=AQHDrNpYounL3QAAAYpe2CJY0YV1bRGryLNqctmxbJ_jfjIcENDhIp8WkwGW8HvpQ2mQFoxCCpdtvZ2rX3j3DxNwyYhguJlvFw&submissionId=251adf5b-b59d-8117-668c-937769f2b409&challengeSource=AgFXWysusKhI7gAAAYpe2MMR72oWlaEK_oRwXtr6wyohlTO_iAH7lxYlpMcobdo&challegeType=AgHWUxveCBVoRwAAAYpe2MMUkJFZCdwhvUWjoQABQhr4zvEE1Y8dnl4&memberId=AgHQKphGaFQNmQAAAYpe2MMWx5mKQsVuU4Gr5W8gA-PJZbM&recognizeDevice=AgGRpDhatMOFfwAAAYpe2MMZTesC5Np1aYtQRxW4i8b5QFMUJZFC
Like the lines "Significant positive impact"
· exploration of opportunities around its personalised oncology software offering.
Dr Sargent has also been Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK.
Https://www.londonstockexchange.com/news-article/PYC/senior-management-update/16108410
Pete is from Nasdaq listed company and NIHR
Long read, please bare with me! A bit of back ground.
In mid August, the company updated its significant shareholders list.
The 2 that were there, have now gone, probably because their holding was diluted after the pathetic raise ( which still irks me )
A new name appeared " Gary Marshall " and yes, that name is i would add, quite a common name. So, it could be anyone of the 1000's of GM's in the UK or world.
Rightly or wrongly, i have looked for GM's working in the pharma industry. They should have a better understanding of what it is PYC are trying to do and accomplish especially within "Precision Medicine" and their so called "Dosing tool"
However, we know that 1 of the names now not on the list ( and believe to still be holding ) is Zahid Ali. He works for a pharma company ( UCB ) .
So after mentioning it last night, and some great insights from GordonBennet1 as to why it would not be 1 of the GM's i mentioned in another industry.
It leaves 2 GM's, both in pharma areas. 1 works for Repare Therapeutics, the other is a GM who works for PSC Biotech.
Doing some digging on PSC, https://biotech.com/ they help various companies in many sectors.
On their website, they can help with "Regulatory approval" https://biotech.com/service/regulatory-affairs/ & "engineering" https://biotech.com/service/engineering/
"Personalised Medicine " thou its a US site so Persoanilsed is with a Z instead of a S !https://biotech.com/service/
You are probably thinking what has this got to do with PYC?
PYC have their dosing tool, which has been used within Doseme for a few years now ( thou there is some conjecture on this ) It has long been mooted that they want to expand it & be more commercial, especially within the USA pharma field. To do this, their "tool" will need Regulatory approval, especially with the FDA, and PSC help with that. Also FDA have a new thing called "project optimus" & PYC are one of the 1st UK coys attempting to trail blaze this initiative.
PSC say they can help with software and many other things that can get a product off the ground.
There could also be the thorny issue that if this is the Gary Marshall that works for PSC, and has got wind of what PYC are planning to do, and could even be the project leader ( his role ) then how does he get 3,2% of PYC, would it be legal?
Zahid Ali went above 3% days after the Doseme or ( DosemeRx as it was ) deal was released, and although he was not involved in anyway, as a industry "insider" it is hypothosised he could see the benefits of it. Just a real shame that after 3 years, nothing has really come of it. ( THRC who owned Doseme, sold then last year )
Anyway, that is my line of thinking, and as i have said numerous times, clutching at straws, and 1 day i maybe right!
Thanks GB1 for that insight.
Must admit the more i read about PSC Biotech i see quite a few links as to where they could help PYC with a few things, however, if it is the same GM who works there, he'd be privy to private comms?
Https://uk.linkedin.com/in/gary-marshall-1b831215
It could be this one, or others listed on the same page.
He has no pharma experience. Thou do you need that experience to make money?
The only Gary Marshall's that i can see that works in pharma are these: https://www.linkedin.com/in/gary-marshall-5873094?challengeId=AQFbwu0UO7ZeNAAAAYpXhkfFs2HSA1rO8KtgyAfJo4ciT7T-iF7ONPzVeTw00Y7QchiA12RGOIvVFOLbVOoczCK4ZY-gdk-6Jw&submissionId=b7af259f-042e-8117-8ba9-912167ae2261&challengeSource=AgHipP0LYNFV-wAAAYpXhpfYXcRJJeVDv75v5quaXw-PySw9H7R-n2yBdJ0rh0o&challegeType=AgHRJvjyhmLQuwAAAYpXhpfbaHfKYtC8HOA0nkoXCK4SjUlH-XROagU&memberId=AgGcPjaPOGFCfwAAAYpXhpfeKlxB6sN3JovWPLjwBtbZiWE&recognizeDevice=AgEI5wU9JZwKGgAAAYpXhpfhH1C3wpJhFmJG1FBCA6wb_Hk3dQ47
And
https://theorg.com/org/repare-therapeutics/org-chart/gary-marshall
Both of them are interesting.
Tar SFU, thats over 2% of the company.....wonder if its the new TR1? guess we may not know for ages?
Another nice day.
Was great watching the live trades go thru.
Went thru 2p first, dropped back, and then thru it again, only to fall back near the end.
A delayed 2.9m print showed up (poss a sell?)
There will be no TR1 RNS for Mr Marshall, as i believe its up to the individual ( as SFU says ) for them to inform the company. So even if Mr Marshall or the previous 2 individuals or anyone else is buying and going over 3% we will probably not know till next significant shareholders list is updated in Feb 2024! That is unless they wish to make themselves known to the company.
I am looking for a biotech/pharma company based in the UK with a "lead asset" its a needle in a haystack, even checking clinical trials is not showing anything concrete.
Its good that the RNS yesterday afternoon did show the price (125k) however, the company in question wants to remain unknown. Its the opposite with MerckGroup, they are happy to have their name with PYC, but not show the contract value(s)
Apart from contracts that could land anytime, we have a new COO to be announced ( imminently ) and interims in late September.
Looks like the over hang from the placing has be bought. #
I wonder that as its 1st September tomorrow, they will release the news of the new COO?
Lovely day today, however for us long term sufferers there is a long way to go yet.
Its great we have had contracts in 1 day, and 1 has a price in it.
Obelix, i read your posts, it really bothers me that JM does not the value on the contracts, but that may well be down to NDA's etc.
Here is my post from a few weeks ago about our biggest collabs etc:
Excellent summary of the potential spending that cone to PYC from long established clients, for confidentiality PYC often aren't allowed to day much but the recent contract used the word "SUBSTANTIAL: which clearly shows q step change from usual .
PYC have recently had new collabs from Bicycle, who raised appox $240m.
They helped with Cellcentric with CCS1477 ( now inobrodib )and they have just raised approx $20m and had fast track orphan status from FDA.
Numab secured $110m funding in 2021.
You could hope that a fraction of those $ or £ raised ( at least ) could come PYC's way to help with projects either already started or in the future from these companies?
Then there is the 6m from VAL for (201) if that ever gets off the ground that is.
If you look at the Numab pipeline link i posted earlier, you can see that 8 of the 9 projects have partners, including: 3SBio/Sunshine Guojian, Boehringer Ingelheim, Eisai, CStone, Ono, Kaken, and Tillotts.
They have 1 which is fully owned by themselves which is NM32-2668
Its not out of the realms of possibilities that IF PYC are helping Numab on pipeline with a partner, then said partner could also be informed of PYC work?
Also, i noted the new TR1, which appeared on Friday, and no one ( apart from SFU ) has even mentioned it anywhere here, Twitter or Telegram which i find amazing tbh.
Normally if a company release's this news or its put on website, the relevant name is dissected, however, as no one is really not bothered about PYC, this new name is just a after thought?
This is from 2022 Q&A
Q: Could you comment on your work or involvement with Merck KGaA?
We’ve been engaged with Merck for many years, even before I arrived in the Company. As you will recall shortly after my arrival in the Company in around December 2017 we signed our first umbrella agreement with Merck where they aspired to spend at least €500,000 with us annually. I’m proud to say that we’ve done at least that every year since then. It’s not guaranteed and yet they’ve come back for more on a regular basis. Our close relationship has survived management changes and reorganisations and importantly our relationship with them today, I believe, is the best it’s ever been. Our work provides a key input to a number of important decisions they make relating to their active clinical programs and that makes me very proud. This relationship is a very real validation of our Virtual Tumour platform.
As usual no contract amount in the RNS, hence RNS reach.
However, i assume that this i worth 300k to ???k
This is based on the usual Merck spend for the last 3 yrs?
In April update, PYC reported a 300k shortfall, due to long standing client cut backs ( again assume Merck )
Merck used to account for 80% annual revenues.
This deal is also on top of the diversification mentioned by PYC earlier this year.
PYC has a new TR1 (significant shareholder) The info was posted on PYC website on Friday. I have been sat on this info, waiting to see if anyone else spotted it.
The new name is Gary Marshall, now holds 3.32% which i believe is a smidge under 4m shares??
The 2 other names that were on the register have now gone, no doubt gone under 3% due to the dilution after the last raise.
Who is this Gary Marshall?
Checking thru the interweb, a few pop up depending on what you put in the search?
https://www.morningstar.co.uk/uk/news/AN_1665747059515039700/in-brief-assetco-new-chief-financial--operating-officer-buys-shares.aspx
https://www.londonstockexchange.com/news-article/MCL/director-pdmr-shareholding/15833681
https://www.linkedin.com/in/gary-marshall-5247b110?original_referer=https%3A%2F%2Fwww.google.com%2F
This guy is interesting.
https://www.reparerx.com/
Look at what they do, and they also look into DNA repair/damage which fits in nicely with todays RNS with Merck
They are based in Boston ( same as Ankyra ) and also went to this years AACR ( same has PYC )
Now, there is zero link between PYC and Repare,
As with PYC, its all ifs buts and maybe's!
Over at VAL, they have sent out their half year report.
Re VAL201...."we maintain good lines of communications with the TheoremRx team to ensure that they are focussed on securing the financing which will enable the VAL201 sub-license to complete. "
So nothing new there then.
The RNS proof reader did not see spelling issue with "Focussed" should be 1 S?
Have suddenly sprung into life.
We would like to invite you to our webinar “From Theory to Practice: Maximizing Aminoglycoside Efficacy with AUC-guided TDM” on September 19 at 8pm ET/September 20 at 10am AEST.
Join featured speaker, Tony Lai, Senior Pharmacist, Antimicrobial Stewardship/Infectious Diseases, as he makes the case for AUC-guided therapeutic drug monitoring (TDM) of aminoglycosides.
What does this mean for PYC?
on this occasion, nothing. However, its good to see Doseme doing a webinar.
Yep, everything at 95 is a sell, anything over 96.0 appears to be a buy.
If you are trying to get 1M, then its less than £10k